CompletedNot Applicable

Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation

United States817 participantsStarted 2017-01

Plain-language summary

The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The study will also assess reasons for not prescribing OA to prevent thromboembolic complications in patients with NVAF seen in ambulatory care, and patients' perspectives of non-use of OA for treatment of NVAF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: A patient must meet all of the following criteria to participate in this study: * Able and willing to complete the survey; * Diagnosed with nonvalvular atrial fibrillation and CHA2DS2-VASc ≥ 2; * Not currently treated with oral anticoagulants according to the PINNACLE Registry data; * Enrolled in the PINNACLE Registry; * Last physician office visit within the prior 18 months; and * Age ≥ 18 years. Exclusion Criteria: A patient will be excluded from participating in the study for any of the following reasons: * Patient is no longer being followed at the local practice; * Patient declines participation; and/or * Patient is unable to speak or read English.

What they're measuring

A benchmark rate of OA treatment in patients with NVAF

Timeframe: Baseline

Trial details

NCT IDNCT02919982

SponsorBaim Institute for Clinical Research

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-05

View on ClinicalTrials.gov More Nonvalvular Atrial Fibrillation trials